(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 November 2012 (29.11.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/159960 A1

(51) International Patent Classification:
A61K 9/48 (2006.01) *A61K 31/4545* (2006.01)
A61K 47/10 (2006.01)

(21) International Application Number:
PCT/EP2012/059147

(22) International Filing Date:
16 May 2012 (16.05.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

1727/CHE/2011	20 May 2011 (20.05.2011)	IN
61/499,856	22 June 2011 (22.06.2011)	US
11305923.2	13 July 2011 (13.07.2011)	EP

(71) Applicant *(for all designated States except US)*: **AVENTIS PHARMACEUTICALS INC.** [US/US]; 55 Corporate Drive, Bridgewater, NJ 08807 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BADABHAGNI, Sudhakara Rao** [IN/FR]; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **JAISWAL, Nilesh** [IN/FR]; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **KHULLAR, Praveen** [IN/FR]; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **PRASAD, Kum** [IN/FR]; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR).

(74) Agent: **CARION-TARAVELLA, Brigitte**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2012/159960 A1

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING FEXOFENADINE

(57) Abstract: The present invention relates to a pharmaceutical formulation of fexofenadine hydrochloride in a solvent system suitable as a liquid fill composition. In another aspect, the invention also relates to a process for the preparation of the said pharmaceutical formulation and the use of said composition for the preparation of a drug for the treatment of allergic reactions in a patient.